Boston Scientific (BSX) is drawing sustained bullish sentiment from analysts who are projecting roughly 30% year-over-year earnings or revenue growth by 2026, a pace that would materially outstrip the broader medical device sector. The optimism appears rooted in the company's expanding product portfolio and execution track record, though the specific growth drivers cited vary across analyst reports. At that growth rate, BSX would be repricing relative to med-tech peers whose forward multiples have compressed on rate and reimbursement pressures. The key variable to monitor is whether organic volume growth or margin expansion is carrying the projection, as each implies a different risk profile for the stock. Investors will be watching upcoming earnings calls and guidance revisions for hard data points that either validate or stress-test the 30% target. Any shortfall in product launch cadence or pricing power in key segments could quickly shift the consensus tone.
Indian startups raised $5.2 billion across 501 deals in H1 2026, down 9% in value but up 7% in deal count year-on-year, per the Inc42 Indian Tech Startup Funding Report. The drop is driven by fewer mega-rounds, while AI funding surged 317% and growth-stage deal activity hit a multi-year high.
The BSE Sensex fell 893 points and the Nifty 50 shed 279 points on June 30, 2026, wiping out roughly Rs 6 lakh crore in investor wealth in a single session. Both indices dropped 1.16%, closing at 76,200.68 and 23,824.10 respectively.
Kotak Mahindra Bank shares fell nearly 3% to Rs 397.6 after CEO Ashok Vaswani announced plans to exit the bank. Investor concern now centres on succession timing and whether the bank's ongoing digital and deposit-growth strategy will stay on track.
South Korea's Kospi dropped 3% at Monday's open while Japan's Nikkei fell 1%, as escalating US-Iran conflict triggered a broad risk-off move across Asian markets. South Korea's heavy reliance on Middle East oil imports makes it especially vulnerable to geopolitical shocks of this kind.
